Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank57
3Y CAGR-25.9%
5Y CAGR-0.6%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-25.9%/yr
vs -9.9%/yr prior
5Y CAGR
-0.6%/yr
Recent deceleration
Acceleration
-16.0pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $48.76M | -37.0% |
| 2024 | $77.41M | +1912.0% |
| 2023 | $-4.27M | -103.6% |
| 2022 | $119.93M | +71.2% |
| 2021 | $70.04M | +39.7% |
| 2020 | $50.13M | +257.2% |
| 2019 | $-31.89M | -117.5% |
| 2018 | $182.17M | +110.8% |
| 2017 | $86.41M | +149.2% |
| 2016 | $34.68M | - |